MedTrace Logo

Zenith Thoracic Alpha (ZTA) Post-Market Data Collection

NCT06094127 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-02-27

No results posted yet for this study

Summary

This study aims to gather real-world clinical data demonstrating the continued safety and performance of the a marketed stent graft (Zenith® Alpha Thoracic Endovascular Graft \[ZTA\]) and collect longer term follow-up to better understand clinical outcomes associated with the expected lifetime of the device.

Conditions

  • Thoracic Aortic Aneurysm
  • Penetrating Aortic Ulcer

Interventions

DEVICE

Endovascular aortic treatment

Use of ZTA to treat diseases in the descending thoracic aorta, such as thoracic aortic aneurysm and penetrating aortic ulcer.

Sponsors & Collaborators

  • Cook Research Incorporated

    lead INDUSTRY

Principal Investigators

  • Nikolaos Tsilimparis, MD · Klinikum der Universitat Munchen

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-06
Primary Completion
2029-12-01
Completion
2034-12-01

Countries

  • France
  • Germany
  • Italy
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06094127 on ClinicalTrials.gov